Primary treatment of rectal cancer was the focus of the second St. Gallen European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Cancer Conference. In the context of the conference, a multidisciplinary international expert panel discussed and voted on controversial issues which could not be easily answered using published evidence. Main topics included optimal pretherapeutic imaging, indication and type of neoadjuvant treatment, and the treatment strategies in advanced tumours. Here we report the key recommendations and summarise the related evidence. The treatment strategy for localised rectal cancer varies from local excision in early tumours to neoadjuvant radiochemotherapy (RCT) in combination with extended surgery in locally advanced disease. Optimal pretherapeutic staging is a key to any treatment decision. The panel recommended magnetic resonance imaging (MRI) or MRI þ endoscopic ultrasonography (EUS) as mandatory staging modalities, except for early T1 cancers with an option for local excision, where EUS in addition to MRI was considered to be most important because of its superior nearfield resolution. Primary surgery with total mesorectal excision was recommended by most panellists for some early tumours with limited risk of recurrence (i.e. cT1-2 or cT3a N0 with clear mesorectal fascia on MRI and clearly above the levator muscles), whereas all other stages were considered for multimodal treatment. The consensus panel recommended long-course RCT over short-course radiotherapy for most clinical situations where neoadjuvant treatment is indicated, with the exception of T3a/b N0 tumours where short-course radiotherapy or even no neoadjuvant therapy were regarded to be an option. In patients with potentially resectable tumours and synchronous liver metastases, most panel members did not see an indication to start with classical fluoropyrimidine-based RCT but rather favoured preoperative short-course radiotherapy with systemic combination chemotherapy or alternatively a liver-first resection approach in resectable metastases, which both allow optimal systemic therapy for the metastatic disease. In general, proper patient selection and discussion in an experienced multidisciplinary team was considered as crucial component of care.
Introduction
The second St. Gallen European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Cancer Conference 2014 focussed on the primary treatment of rectal cancer. A representative faculty of expert surgeons, radiation oncologists and medical oncologists, pathologists and gastroenterologists reviewed the current knowledge and discussed treatment recommendations in a panel session based on a moderated consensus process. The main interests were controversial issues which could not be easily answered through study of published evidence and guidelines [1e4] . As in the St. Gallen Breast Cancer Conferences, the panel was asked to assess the available evidence and vote on recommendations using a precirculated set of questions. A detailed review of the presentations has been published elsewhere [5] . Here, we summarise the key discussion points of the panel members.
The treatment strategy for localised rectal cancer is based on clinical examination together with endoscopy and imaging using either magnetic resonance imaging (MRI) and/or endoscopic ultrasonography (EUS) and is currently guided mainly by the risk of local recurrence, e.g. European Society for Medical Oncology (ESMO) [1] or the National Comprehensive Cancer Network (NCCN) guidelines [4] . The most important aim is the prevention of recurrent disease with as little treatmentrelated morbidity as possible and with maintained bowel, sexual and genitourinary function. Treatment options vary from organ-preserving local excision in very early tumours to a combination of radiochemotherapy (RCT) with extended surgery in locally advanced disease. If the risk of recurrence or lymphatic invasion is low (i.e. in cT1 sm1 tumours without nodal involvement and without unfavorable prognostic factors like poor differentiation or venous invasion), local excision may be sufficient. Primary extended surgery with total mesorectal excision (TME) is discussed for early tumours with limited risk of recurrence (i.e. mrT1-2 or mrT3a spread <5 mm, mrEMVI negative with clear TME plane), whereas all other substages are commonly considered for multimodal treatment. In any case, optimal pretherapeutic staging is essential for any treatment decision.
There is an ongoing debate on the ideal modality and sequence of combination treatment for intermediate stages. Influencing factors are depth of extramural spread, the distance from the anal verge, the circumferential location, the distance of the tumours from the mesorectal fascia, and the involvement of extramural vessels (extramural vascular invasion [EMVI]) or nerves. This uncertainty may be exemplified in T3b or less tumours in the upper or middle rectum, which have a low risk of local failure, if the tumour is >1 mm from the mesorectal fascia (MRF). For these stages, the ESMO guidelines consider primary surgery followed by adjuvant treatment if judged necessary after pathological evaluation [1] , whereas the NCCN guidelines favour preoperative chemotherapy or preoperative combined RCT and recommend adjuvant treatment for all patients [4] .
The choice and sequence of multimodal treatment combinations was another topic. In general, preoperative treatment is preferred because it is less toxic and more effective in local control than adjuvant treatment. Accepted standards for the preoperative approach are either the use of a short course of radiotherapy (SCRT) over 5 d followed by immediate surgery or the combination of fluoropyrimidine-based chemotherapy with a long course of conventionally fractioned RCT followed by surgery after 6e8 weeks. Compliance and immediate toxicity are in favour of SCRT, whereas RCT has the potential of downsizing and downstaging of tumours. In contrast, the standards for postoperative treatment are less well defined. Adjuvant chemotherapy (ACT) is performed in many patients who had already received preoperative RCT, even though the evidence is limited. Postoperative RCT is recommended for all pT3/T4 and/ or pNþ tumours which had not been treated preoperatively, a recommendation which may not hold in limited disease (i.e. T3 tumours) or in tumours of the upper rectum.
Methods
In preparation for the panel session, which was held on 8th March 2014 with 27 experts, existing guidelines were used to identify areas of uncertainty in order to define the topics for debate. Over 100 questions were circulated between panel members, of which 42 were retained for the joint discussion. During the session, the panel members were asked to assess and comment on the existing data and to recommend treatment strategies as expert opinion. Panel members were given the opportunity to comment on the questions, before and after an electronic vote. Here, we summarise the extent of agreement or disagreement of the panel members.
Even though care was taken to invite a representative spectrum of panellists from relevant disciplines, the general applicability of their conclusions may be limited by an unequal distribution of disciplines and/or underrepresentation of some regions of the world. In addition, generalised treatment recommendations depend also on patient selection. The statements to follow are usually meant for reasonably fit patients with no relevant comorbidities. Many patients in clinical practice will not match the hypothetical model and treatment decisions will need to be made on an individual basis.
Pretherapeutic local staging
Accurate pretherapeutic imaging of the tumour and lymph nodes is the key component of any treatment decision, in addition to clinical examination, endoscopy and screening for distant metastases. The vast majority of the expert panel members considered the inclusion of MRI (91% of the panellists) or even MRI þ EUS (33%) as mandatory for 'local imaging of the tumour' with no role for EUS or computed tomography (CT) scans alone. Sole exceptions are T1 tumours where organsparing surgery or endoscopic en-bloc resection is considered as a potential treatment option. There, EUS was recommended by 88% of the panellists because of its excellent resolution and its superior definition of the infiltration depth, with 38% opting for additional MRI.
To detect 'lymph node involvement', MRI was also considered to be the best imaging tool (92% for MRI alone, 8% together with EUS). The validated parameters using MRI are irregularity of the border and mixed signal intensity [6, 7] . Using ultrasound, the roundness, echogenicity, and imaging pattern (architecture) have been described.
Several meta-analyses or systematic reviews examined the quality of T and N staging with various imaging techniques. Summary results of the largest series are listed in Table 1 . However, the meta-analyses incorporating such a wide range of imaging standards must be interpreted with caution as many of the older and larger studies included used low-resolution techniques and undefined diagnostic assessment criteria.
Overall, an acceptable accuracy was demonstrated for all three imaging modalities. In a meta-analysis reviewing nonehigh-resolution techniques and older MRI studies, EUS performed significantly better for the definition of 'invasion into the muscularis propria', i.e. for the distinction of T1 and T2 tumours, where its specificity reached 86% (95% confidence interval [CI]: 80e90%) compared with 69% (95% CI: 52e82%) for MRI [8] . The sensitivity was high in both groups (94%), indicating a greater potential for overstaging with MRI when using older low-resolution techniques and imprecise definitions of assessment of tumour spread [8] . However, the modern high-resolution techniques have proven MRI to assess depth of spread accurately to within 1 mm of histopathology assessments [9] . The use of MRI in selecting patients for local excision rather than TME surgery now hinges on the assessment for the degree of preservation of the muscularis and submucosal layers which enable a judgement of the safety of the excision planes [5] . CT imaging was not compared because of the insufficient resolution of the layers of the rectal wall.
Results for lymph node involvement were comparable for all three modalities with low-sensitivity rates (55e69%). However, EUS can technically only be used to evaluate the perirectal lymph nodes, whereas MRI using high-resolution techniques identifies disease within the entire mesorectum and pelvic sidewall compartment. Based on the morphologic criteria of mixed signal intensity and irregularity of the nodal border rather than size criteria, the prevalence of pelvic sidewall metastatic disease is 11%, and MRI detection of patients with pelvic sidewall nodal disease is associated with poorer overall disease-free survival (DFS) unless RCT is given [9] . CT is used to examine the regional lymph nodes in the pelvis and retroperitoneum. The accuracy is related to T-stage and increases with lymph node size [10] . In a series of EUS-staged rectal cancer, lymph node metastases of increasing size were observed in the resection specimen in 29% of pT1 tumours (median size of 3.3 mm), in 30% of pT2 tumours (median size of 6.2 mm), and in 46% of pT3 tumours (median size of 8.0 mm) with resulting accuracies of preoperative imaging of 48% in pT1, 67% in pT2, and 84% in pT3. Measuring only the size of lymph nodes leads to substantial overstaging because benign reactive nodes are seen in many patients and can enlarge to any size [11] . Nodal heterogeneity or penetration of the outer rim which results in border irregularity in high-resolution images are well-known features of malignancy [6, 12, 13] which may be used as additional parameters if there is sufficient imaging resolution in larger nodes.
MRI will depict lymph nodes with high sensitivity and the majority of benign reactive nodes will be positioned close to the mesorectal fascia posteriorly. However, audit of specimens has shown that lymph nodes are an extremely rare cause of circumferential resection margin (CRM) involvement occurring in <1.3% of patients and, therefore, caution should be exerted when recommending neoadjuvant therapy solely because an encapsulated lymph node is visualised close to the mesorectal fascia [12] . Both EUS and CT are unable to identify the mesorectal fascia [8] . Optimised MRI performed according to standardised protocols by trained investigators is able to predict the extent of tumour outside the muscularis propria within a tolerance of 0.5 mm and correctly predicted a clear CRM in 94% in the MERCURY trial [14] , with 1 mm as best cut-off distance for predicting CRM involvement [15] . Follow-up data indicate that MRI-based pretherapeutic definition of an involved CRM is an independent prognostic factor for 5-year overall survival (62.2% in Table 1 Pooled estimates of sensitivities and specificities of the routinely used imaging modalities for local staging of rectal cancer. MRI-CRM clear as compared to 42.2% in CRM involved), for DFS (67.2% versus 47.3%) and for local recurrence with a hazard ratio of 3.5 (95% CI of 1.53e8.0, p < 0.05). MRI-defined EMVI is an additional independent poor prognostic factor for both local recurrence and for DFS in stage II/III rectal cancer [16] . Examples for a minimum technical requirements and reporting are given in Table 2 .
Do T3 rectal cancers always need RCT or radiotherapy?
Preoperative chemoradiation (RCT) or short-course preoperative radiotherapy (SCRT) are considered standard of care for patients with clinical stage II and III rectal cancer because of the risk of local recurrence with surgery alone and because of the postulated potential for sphincter preservation. Many multidisciplinary teams advocate SCRT or RCT for all patients with rectal cancer staged as cT3 regardless of nodal status, tumour location, and proximity to other structures or extent. However, omitting RCT or SCRT would offer the benefit of improved wound healing, less frequent anastomotic leaks, avoidance of long-term radiation toxicity, and a smaller risk of secondary malignancies [17e21].
The 'site of the primary tumour location and the presence of lymph node metastases' appear crucial to decision making. The consensus panel was asked to choose the optimal preoperative treatment (SCRT, RCT, or primary surgery with no additional multimodal therapy) for three different clinical situations. For units where quality-controlled TME is done, and for easily resectable cancers of the mid-rectum with no detectable lymph node metastases (cT3 cN0), 71% of panellists did not feel combination treatment was required for all patients, but 25% did, albeit there was some debate as to the definition of 'easily resectable', which may be defined as tumours with less than 5 mm infiltration depth into the mesorectal fat and at least 1 mm distance from the mesorectal fascia (see also Table 3 ). In contrast, for cT3 cN0 low rectal cancer, 66% voted that SCRT or RCT were necessary. The majority of the panellists also considered RCT the best option for treating easily resectable rectal cancer of the mid-rectum with lymph node metastases (cT3 cNþ). Only 20% voted that neoadjuvant treatment was not required, and 75% of the panellists considered SCRT to be an appropriate alternative option in this situation. In the interval, data have emerged from the multicentre MERCURY 2 trial which has shown that almost half of patients with tumours arising <6 cm from the anal verge when staged by MRI Table 2 Minimum technical requirements for MRI and its interpretation and reporting in pretherapeutic staging of rectal cancer [76] .
MRI staging of rectal cancer
Technical requirement -1.5 or 3 Tesla system with phase array coil -Standard T2 fast-spin echo for initial localisation/planning -High-resolution T2-weighed images: minimal voxel density of 1.1 mm 3 , e.g. 3-mm sections with in-plane resolution of 0.5e0.8 mm Scanning protocol -Sagittal T2-weighted fast-spin echo to identify the tumour -Large field-view axial sections of the whole pelvis -High-resolution axial images of the tumour and adjacent tissues (perpendicular to the rectum long axis at the tumour level) -Lymph node assessment: high-resolution axial imaging of the upper tumour border up to L5/S1 -Low tumours: high-resolution coronal imaging of levator muscles, sphincter complex and their relation to the rectal wall -Sessile lesions/polyps: high-resolution sagittal series are not invading the distal TME/intersphincteric plane. Rectal cancers localised in the upper third of the rectum were exempt from the discussion as they are usually treated by analogy with colon cancer.
A large majority of panellists believe RCT to be required if clinical staging suggests the status is 'cNþ'. Also, when MRI shows a 'threatened/breached CRM' (10e15% of cases), or in cancers which require surgical resection beyond the conventional TME and in clinically unresectable cancers, downstaging is required and RCT was considered the modality of choice [22] . As a consequence, 66% of the panellists considered it necessary to distinguish between patients with MRI criteria which predict a high risk of local recurrence versus those with a high risk of metastases (i.e. EMVI) and tailor treatment appropriately.
The results from the Dutch TME trial [23] show a marginal benefit for SCRT in stage II (N0) patients (local recurrence [LR], 5.3% versus 7.2%), arguing against any preoperative therapy, but the MRC CR07 trial [24] demonstrated a reduction of LR from 6.4% to 1.9%, again with SCRT. However, none of these trials nor any of the chemoradiation trials published in the last decade have shown any difference in overall survival [25e28]. None of these trials used modern MRI staging techniques to assess CRM, mrEMVI status or depth of tumour spread beyond the muscularis propria. Norwegian population data suggested low rates of local recurrence for patients with pathological findings of a clear CRM >3 mm and pN0 [29] . Several groups, which are known to perform high-quality surgery, have recently explored omitting radiotherapy when MRI suggests the tumour is easily resectable and the mesorectal fascia is not threatened regardless of nodal stage. This omission is associated with the local recurrence rates of <5% [30e33].
The 'quality of surgery' is crucial. The majority of local recurrences historically reflected inadequate mesorectal resection [34] , which is a common finding on postoperative MRI after partial mesorectal excision [35] . Careful dissection particularly in the posterior aspect of a TME specimen with its higher prevalence of lymph nodes is important [36] . Currently, optimal qualitycontrolled surgery in terms of TME in the trial setting can be associated with local recurrence rates of less than 10% whether patients receive radiotherapy or not [37] . There are also significant 'late effects from pelvic radiotherapy' on anorectal, urinary and sexual function [17, 38, 39] , unexplained late cardiac effects [17] , insufficiency fractures in the pelvis [40] , and an increased risk of secondary malignancies after 10 years [20, 21] dall of which need to be balanced against the risk of local recurrence.
Some have, therefore, questioned the routine use of both these approaches (RCT and SCRT). Fluoropyrimidine-based RCT does not employ full systemically active doses of chemotherapy and delays the integration of ACT. Many current investigative approaches in rectal cancer take the view that better results might be obtained by adding and/or extending more intensive chemotherapy into the neoadjuvant setting. The question is, whether radiotherapy is needed at all?
Neoadjuvant long-course RCT versus SCRT
The aims of neoadjuvant therapy in locally advanced rectal cancer (LARC) are to decrease the risk of locoregional relapse and to downsize/downstage tumours that threaten the mesorectal fascia or to facilitate sphincter preservation. Long-course RCT or SCRT is currently used (Tables 4 and 5 ). In the latter, the original protocol scheduled the operation for the week following radiation therapy. More recently, protocols for delayed surgery have been evaluated in clinical trials [41] .
The consensus panel discussed the indications for RCT and SCRT in various clinical situations. Rectal cancers localised in the upper third of the rectum were exempt from the discussion as they are usually treated similarly to colon cancer.
For easily resectable rectal cancer of the mid-rectum with no detectable lymph node metastases (cT3 cN0), an equal number of panellists favoured either option, if a combined therapy was indicated. In the trials directly comparing SCRT and RCT [19, 42] , LR rates were similar and 75% of the panellists considered SCRT to be acceptable in this situation. As discussed above, the indication for preoperative therapy in this group of patients has been questioned since the introduction of TME has significantly reduced the rate of LR.
However, more than half of the panellists considered RCT the best option for cancer of the mid-rectum with lymph node metastases (cT3 cNþ) even when it was easily resectable, with only very few voting against any neoadjuvant treatment. Both the Dutch and the MRC trials [23, 24] show a significant decrease of LR in nodepositive tumours in the TME era. However, analysis of the surgical specimen quality in the CR07 trial has also shown that pelvic recurrence rates were 20% for poorgrade TME compared with only 6% for good-quality CRM-negative TME node-positive patients which compared favourably with 5% local recurrence rates in node-negative patients in good-grade TME specimens [37] . Approximately 18% of audited TME specimens in the Dutch TME trial were poor grade and preoperative CRM status had not been assessed in either CR07 or Dutch TME trials. Therefore, a neoadjuvant approach seems indicated in node-positive disease if the quality of the TME surgery is in doubt and preoperative assessment of the MRI-validated prognostic factors linked to local recurrence, i.e. mrCRM, mrT substage and mrEMVI, is not established.
For rectal cancer situated in the 'low rectum' (without lymph node metastases), three quarters of the panellists favoured RCT and only one quarter considered SCRT the best option. The risk for LR for tumours in the low rectum even in the TME era and after neoadjuvant therapy is relatively high (10.1% LR in the German trial) [43] . Implementation of an MRI-based low rectal cancer staging classification enables identification of patients for primary surgery with a 98% clear margin rate in just under half of the patients presenting with low-risk rectal cancers at <6 cm from the anal verge. Preoperative therapy of high-risk MR low rectal cancer tumours followed by a good mrTRG and regression of tumour from the intersphincteric plane results in 0% pCRM rates. A poor response necessitates the use of a beyond TME approach in order to achieve clear margins either by extralevator APE or in some cases exenterative surgery [44] .
The role of SCRT was first established in the 1990s by a series of randomised trials [45e47] in resectable and early rectal cancers with the aim of reducing the risk of Table 4 Comparison of treatment and performance characteristics of SCRT or RCT for rectal cancer. local recurrence, which was 20e30% after surgery alone, reflecting the suboptimal surgical practice at that time. Two subsequent, more modern trials early in the TME era, addressed the key question: did SCRT simply compensate for poor surgical technique? These trials tested whether SCRT still reduced local recurrence even if TME was performed [24, 46] . In the control group, postoperative radiotherapy or RCT was intended to be given in the event of a histopathological positive CRM in the Dutch TME study and the CR07 trial, respectively. Both trials demonstrated a reduction in local recurrence, but overall survival was not improved, and the risk of metastases predominated over local recurrence [21, 24, 37, 46] . The second radiation option is combined RCT with daily radiation fractions of 1.8 e 2.0 Gy up to a total dose of 45 e 50 Gy. Concurrently, a fluoropyrimidinebased chemotherapy is given, most often infusional 5fluorouracil (5FU) or capecitabine, which has been extrapolated from the successful strategy of postoperative 5FU-based RCT for patients with stage II or III rectal cancer. Several groups performed randomised trials of preoperative 5FU-based RCT and demonstrated an improvement in locoregional control [25e27] but this did not translate into an improvement in DFS or OS. Only in more advanced unresectable or borderline resectable cases did RCT result in improved resectability and DFS [22] .
With the increased accuracy of preoperative imaging to define the potential for curative resection, RCT has been taken up more widely, particularly when the CRM is predicted to be compromised. In contrast, SCRT and immediate surgery is primarily not intended to achieve significant shrinkage or pathological downstaging. The Dutch TME trial found no significant difference in TNM stage distribution between SCRT and surgeryalone groups [46] , but T-stage downstaging was observed if surgery was delayed for more than 10 d following the completion of SCRT [48] . Further extension of the interval following SCRT to surgery of at least 6 weeks does demonstrate more downstaging, but the optimal interval has not been defined [41, 49] . Whether the same degree of tumour shrinkage to that seen with RCT can be achieved with SCRT and an extended interval to surgery is currently unclear. Recent preliminary data from a Polish trial comparing two neoadjuvant treatment protocols (SCRT followed by 4 Â FOLFOX4 or RCT with bolus 5FU/leucovorin (LV) and oxaliplatin) resulted in comparable local efficacy and possibly improved overall survival with SCRT (ASCO GI 2016, Abstract # 489).
Overall, the consensus panel recommended long-course RCT over short-course radiotherapy for most clinical situations in which neoadjuvant treatment is indicated, with the exception of T3a/b N0 tumours with clear mesorectal fascia (>1 mm) where short-course radiotherapy or no therapy were regarded to be equivalent.
Adjuvant chemotherapy
Most cancer-related deaths in patients with rectal cancer are due to distant metastases. ACT in colon cancer reduces the incidence of distant relapse and improves overall survival. In analogy, ACT was integrated into postoperative and perioperative treatment strategies in rectal cancer. However, although ACT after preoperative RCT and surgery is currently recommended in most guidelines [50] , the contribution of the adjuvant part to the benefit of the perioperative therapy had not been formally tested in a randomised trial at the time of the St. Gallen 2014 consensus meeting. The first indication that ACT may not improve local or distant relapse rate after preoperative RCT came from the EORTC 22921 trial [51] and was further questioned in other trials [52e54] (see Table 6 ).
At the consensus session, most panellists (83%) recommended against ACT for cN0/ypN0 tumours. However, for tumours that were initially lymph node positive but became lymph node negative after RCT (i.e. cNþ/ypN0), the panellists' opinion on ACT was divided (pro 41%, con 59%). In cases with histologically confirmed positive lymph nodes after neoadjuvant RCT Table 6 Adjuvant chemotherapy trials in rectal cancer and meta-analysis. (ypNþ), the majority of panellists (77%) voted in favour of ACT. About half the panellists (47%) were in favour of ACT that included oxaliplatin with 16% against this option. When ACT is indicated, most panellists (68%) agreed that a colostomy should be closed after completion of chemotherapy to avoid an interruption that might mitigate the effect of the ACT.
After the consensus meeting, results from a number of clinical trials investigating the role of ACT in this situation were published (Table 6 ). Since these results have the potential to change clinical practice, we compiled the evidence in a table without additional panel voting. These new data do not support the further use of ACT as a standard in mid and low rectal cancer (less than 10 cm from the anal verge) after neoadjuvant RCT and R0 resection, irrespective of T stage and nodal status [55] . However, for upper rectal cancer between 10 and 15 cm from the anal verge, ACT can be considered as standard for lymph nodeepositive tumours (either cNþ before neoadjuvant therapy and/or ypNþ) [55] . This regimen should usually include oxaliplatin (panel: 47% yes, 16% no, 37% abstain), which is supported by data from colon cancer and from a phase II trial in rectal cancer [56] .
Clinical complete response after preoperative longcourse RCT
After RCT, some patients experience a complete clinical response of their tumour. Managing these patients without immediate surgery, but with frequent surveillance presents an option that may obviate the need for a surgical intervention for some of them [57] . To test the limits of this strategy, the panellists were asked whether this 'watch and wait' strategy was also justified in lymph nodeepositive, low rectal cancer. In this situation, the panel was equally divided for and against. Half of the panellists were in favour of 'adjuvant' chemotherapy after achieving a complete clinical response by RCT provided careful follow up was feasible, thus avoiding a primary operation. We did not ask if local excision with organ preservation was also considered as an option.
Rectal cancer with synchronous liver metastases
The incidence of synchronous liver metastases in patients with primary rectal cancer is approximately 15% [58] . The principle treatment goal is complete resection of all primary and metastatic lesions with a curative approach, but the choice and sequence of the available treatment modalities depend on the clinical situation. Patients can grossly be divided into two groups: those with initially resectable and potentially resectable disease after conversion therapy and those patients in whom complete resection of the primary tumour or the metastases will not be achievable.
In patients with 'unresectable metastatic rectal cancer', the primary treatment goal is maintaining quality of life, improving tumour-related symptoms and minimising treatment-related side-effects. Accordingly, if the primary tumour was not going to be removed, the panel voted against pelvic radiotherapy in patients with an asymptomatic rectal tumour and synchronous liver metastases (79% no) and also against local ablative treatment by surgery or radiologic intervention even if the hepatic lesions were small and few (80% no).
Reported mortality after resection of the primary tumour in patients with incurable stage IV colorectal cancer ranges from 1.3% to 16%, which is significantly higher than resection for colorectal cancer in general [59, 60] . For this reason, there is a tendency towards a conservative approach, especially in asymptomatic patients. A deviating loop colostomy (preferably by laparoscopy) is often an effective alternative. Palliative pelvic radiotherapy was analysed in a systematic review by Cameron et al. [62] and showed a pooled overall symptom response rate of 75%, although toxicity results were not available [61] . SCRT with chemotherapy has even been shown to spare palliative surgery in 80% of symptomatic patients in a phase II trial. A stent can be placed to treat obstructing rectal cancer, but endoscopic stenting options for low-lying rectal tumours are limited and may cause significant side-effects. A randomised study by Fiori et al. [63] analysed 22 patients with stage IV unresectable rectosigmoid cancer with symptoms of subacute obstruction. Patients were treated by either endoscopic placement of an expandable stent or diverting proximal colostomy and were followed until death. There were no differences between treatmentrelated morbidity or mortality, but hospital stay and restoration of oral feeding and bowel function were shorter after stenting.
In 'potentially resectable disease', treatment of the primary rectal tumour per se consists of surgery after SCRT or RCT. Most patients with synchronous liver metastases present with advanced rectal disease and, thus, formally have an indication for prior RCT [64] . However, standard RCT based on a fluoropyrimidine-alone chemotherapy backbone likely results in under-treatment of the metastatic disease for a substantial time interval which may be further prolonged by postoperative complications if the rectal tumour is removed first. Therefore, the panel did not see an indication to start with fluoropyrimidine-based RCT in these patients (83% no).
As SCRT and delayed (4e8 weeks) rectal surgery in resectable cancers can result in local tumour regression in 74% of patients and has a low-toxicity profile [65] , it may offer both local control and, more importantly, the opportunity to start systemic therapy almost instantly, optimising the treatment of metastatic disease. The feasibility of such an approach has been demonstrated in a phase II trial, where SCRT was followed by capecitabine, oxaliplatin, and bevacizumab for up to six cycles and surgery 6e8 weeks after the last cycle [66] . Radical R0 surgery of all tumour sites was possible in 36 of 50 (72%) patients. An interim analysis of a randomised trial in patients with fixed cT3 or cT4 or locally recurrent rectal cancer showed this strategy (SCRT þ FOLFOX) achieved a microscopically radical resection (primary end-point) in 73% [67] .
'Systemic therapy alone' can also induce significant response of the tumour. A case series of 22 patients with rectal cancer demonstrated an objective pathological response in 12 patients, including one patient with a complete response [68] . Prior to the start of treatment, symptomatic rectal tumours with clinical signs of obstruction should be decompressed with a colostomy to avoid treatment delays for emergency intervention. However, in patients with an endoscopically obstructing tumour only (with no clinical symptoms or signs of obstruction), a diversion colostomy seems not needed. Patel et al. [69] showed progression to complete obstruction needing surgery in only 2 of 85 patients during neoadjuvant systemic therapy in patients with endoscopically obstructing rectal tumours. As to the panel, all members elected combination regimens for initial treatment.
Traditionally, the strategy for surgical management of colorectal carcinoma with resectable liver metastases was resection of the primary tumour followed by treatment of the liver metastases, with or without perioperative systemic therapy. This approach has been challenged by a 'liver-first approach' because the prognosis is usually related to the liver metastases. Furthermore, the liver-first approach has a higher percentage of patients completing the full treatment protocol and it avoids delay due to complications of rectal surgery [70] . The St. Gallen panel saw a place for the primary resection of a small resectable liver lesion before the start of RCT for LARC (52% yes versus 43% no).
In a systematic review of patients with colorectal tumours, the common treatment sequence in four studies comprised neoadjuvant systemic chemotherapy, liver resection, RCT for the rectal tumours, followed by colorectal resection and ACT; 90 of the 121 (74%) patients in this review completed the full treatment protocol and disease progression occurred in 23 patients (19%). In the study describing patients with rectal cancer only, 73% (16 of 22) completed the full protocol with a 5-year survival rate of 67% and a median progression-free survival of 19 months [71] . Another argument to choose a liver-first strategy in patients with synchronous rectal cancer is the chance of a complete response of the primary tumour after chemoradiation of 15e25% and, thus, the possibility of a wait-and-see policy [72] . Synchronous resection has been proposed as an alternative approach with less abdominal interventions, but this approach has not been compared to others in a randomised trial [73] . An important factor seems to be patient selection by an experienced multidisciplinary team.
In summary, optimised MRI with standardised protocols or MRI þ EUS were considered as corner stones of pretherapeutic imaging. Early tumours with limited risk of recurrence were considered as candidates for primary surgery whereas all others should receive multimodal treatment. In general, long-course RCT was preferred over short-course radiotherapy, if neoadjuvant treatment is indicated. In patients with resectable synchronous liver metastases, a treatment strategy with optimum systemic chemotherapy supported by shortcourse radiotherapy of the primary tumour was the favoured approach.
